- Determine the cytotoxicity of your engineered CAR T-cells against target cells of interest, or against off-target tissue representative cell lines, with an in vitro CAR T cytotoxicity assay.
- A range of CAR T: target cell ratios can be assessed in co-culture assays to elucidate CAR T cytotoxic potency and to determine which conditions are ideal for maximal CAR T activity.
- CAR T-dependent cytotoxicity of target cells is determined via flow cytometric analysis.
- Co-culture supernatants can be harvested and stored for optional downstream multiplexed cytokine quantitation.
Service Overview
About the CAR T-Cell Cytotoxicity Assay
The first chimeric antigen receptor (CAR) T-cell therapy was approved by the FDA in 2017 and CAR T therapies have since shown significant promise for long-term remission in several types of cancers. The FDA released draft guidance documents encouraging researchers to take initiative to evaluate CAR T-cell biological activity in the early stages of CAR T-cell development. CAR T-cell cytotoxicity assays performed at iQ Biosciences can help researchers evaluate their CAR T cellular therapy from both a safety and efficacy perspective. The resulting data can inform starting doses and help researchers screen CAR T candidates to assess.
To assess CAR T cytotoxicity, target cells of interest are labeled with a fluorescent cell trace dye and co-cultured with CAR T cells or control effector cells at several ratios to determine any cell ratio-dependent effects. After incubation, the cells are harvested, stained with a fluorescent viability dye, and acquired via high-throughput flow cytometry, to determine the CAR T-cell-dependent specific lysis of target cells. Co-culture supernatants can be harvested and utilized for cytokine measurement, also performed at iQ Biosciences.